Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Kidney Int. 2021 Jan 4;99(5):1102–1117. doi: 10.1016/j.kint.2020.12.022

Figure 7: Myo9A knockdown decreases Myo9A-actin-calmodulin interaction in immortalized mouse podocytes.

Figure 7:

A) Myo9A siRNA [100nM] induces ~50% decrease in Myo9A mRNA, as compared to wild type control and non-targeting siRNA [100nM]. Myo9A mRNA normalized to GAPDH mRNA, expressed as fold change (mean±SD), n≥3 independent experiments,* indicates p<0.05. B) Representative IB shows that Myo9A siRNA induced ~50% reduction of Myo9A protein, as compared to Wt control and non-targeting siRNA; actin expression level was not altered by siRNAs; n≥3 independent experiments. C) Representative Myo9A IP shows decreased Myo9A-actin-calmodulin interaction in Myo9AKD podocytes (siRNA-treated=KD) as compared to wild type immortalized mouse podocytes (Wt), proportionally to the decrease in Myo9A immunoprecipitated; n≥3 independent experiments.